Document Detail

 Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients.
MedLine Citation:
PMID:  22700626     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Response to hepatitis C treatment is known to differ by race; and, limited data suggests by ethnicity as well. A lower efficacy of HCV therapy in Latinos has been observed; whether higher doses may improve the response is unknown.
MATERIAL AND METHODS: This study used the available data from the patients enrolled in the PROGRESS study and stratified it by race and ethnicity. The primary objectives were to evaluate the early viral kinetic pattern in Latino patients and to assess whether it was improved by higher doses of Peg-IFN alfa-2a and/or RBV, as compared to Caucasian and African American patients.
RESULTS: From a total of 1145 patients, 51 (4%) were classified Latino, 886 (77%) Caucasian, 124 (11%) African American and 84 (7%) other. Latinos had a similar virological response between the treatment groups at week 4; but by week 12, achieved a greater response with the higher intensified dose of peginterferon alfa-2a, and remained so at week 72. Caucasians had a greater response at week 4 and week 12 with the intensified dose; but by week 72, the response became similar between the treatment groups. The virological responses for African Americans were unaffected by the doses; and by week 12, were lower than both Latinos and Caucasians. In conclusion, this retrospective analysis provides further evidence for racial/ethnic differences in the response to peginterferon alfa-2a (40KD) plus ribavirin therapy in patients with HCV. Although the sample sizes in this analysis are small for generalized conclusions, the findings are of importance to physicians treating Latinos.
Maribel Rodríguez-Torres; Juan Burguera; Deana Hallman; José Rodríguez-Orengo; Michelle Echeandia
Related Documents :
22447636 - Efficacy of intratympanic steroid administration on idiopathic sudden sensorineural hea...
22552446 - Treatment of melasma with oral administration of tranexamic acid.
20651016 - Percutaneous vertebroplasty is not a risk factor for new osteoporotic compression fract...
22405676 - The recover i: a multicenter prospective study of impella 5.0/ld for postcardiotomy cir...
24702256 - The cost implications of an early versus delayed invasive strategy in acute coronary sy...
7490796 - Postoperative diaphragmatic dysfunction in patients undergoing open-heart surgery.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of hepatology     Volume:  11     ISSN:  1665-2681     ISO Abbreviation:  Ann Hepatol     Publication Date:    2012 Jul-Aug
Date Detail:
Created Date:  2012-06-15     Completed Date:  2012-10-22     Revised Date:  2013-05-16    
Medline Journal Info:
Nlm Unique ID:  101155885     Medline TA:  Ann Hepatol     Country:  Mexico    
Other Details:
Languages:  eng     Pagination:  450-63     Citation Subset:  IM    
Fundación de Investigación, Río Piedras, Puerto Rico.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
African Americans* / statistics & numerical data
Aged, 80 and over
Antiviral Agents / adverse effects,  therapeutic use*
Biological Markers / blood
Drug Therapy, Combination
European Continental Ancestry Group* / statistics & numerical data
Hepacivirus / drug effects*,  genetics,  growth & development
Hepatitis C, Chronic / diagnosis,  drug therapy*,  ethnology
Hispanic Americans* / statistics & numerical data
Interferon-alpha / adverse effects,  therapeutic use*
Middle Aged
Polyethylene Glycols / adverse effects,  therapeutic use*
Puerto Rico
RNA, Viral / blood
Randomized Controlled Trials as Topic
Recombinant Proteins / adverse effects,  therapeutic use
Retrospective Studies
Ribavirin / adverse effects,  therapeutic use*
Treatment Outcome
Viral Load
Virus Replication / drug effects*
Young Adult
Reg. No./Substance:
0/Antiviral Agents; 0/Biological Markers; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/RNA, Viral; 0/Recombinant Proteins; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:   Gut microbiota and nonalcoholic fatty liver disease.
Next Document:  Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt.